Mark Gnoth

Mark Gnoth is the Head of Bioanalytics and Head of the GLP Test Facility at Bayer Pharmaceuticals, where they lead the department in vivo Pharmacokinetics and Bioanalytics. With over 20 years of experience in the pharmaceutical industry, Mark has developed expertise in drug discovery and development, focusing on bioanalytical methods and human dose prediction. They held various senior roles at Bayer, including Director of Bioanalytics Small Molecules and Head of Bioanalytics and Non-Clinical Pharmacokinetics, contributing significantly to regulatory document preparation and project support. Mark earned a Master and PhD in Biology from Universität Osnabrück and MPI Dortmund.